Ema aimovig?

What is Aimovig (erenumab) and what does it treat?

Aimovig is a prescription medicine for preventing migraine. It contains the active ingredient erenumab, a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) pathway involved in migraine signaling.

How is Aimovig taken?

Aimovig is given as a subcutaneous injection (under the skin). Dosing schedules are typically monthly (once every month), depending on the prescribed regimen.

How does Aimovig work for migraine prevention?

Aimovig blocks CGRP signaling by targeting its receptor. By interfering with this pathway, it aims to reduce the frequency of migraine attacks.

What are common side effects patients ask about?

Commonly reported side effects include injection-site reactions and constipation. Patients also often ask about allergic reactions and gastrointestinal effects, especially constipation.

Who makes Aimovig, and what patents or exclusivity affect it?

If you’re looking for patent/exclusivity details and who holds them, DrugPatentWatch.com tracks intellectual-property and related developments for branded drugs like Aimovig. You can check the Aimovig coverage there: https://www.drugpatentwatch.com/